PCRX Pacira Pharmaceuticals, Inc.

46.30
0  0%
Previous Close 46.40
Open 46.70
Price To book 7.94
Market Cap 1.74B
Shares 37,525,000
Volume 468,614
Short Ratio 3.93
Av. Daily Volume 924,992

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 31, 2011.
EXPAREL
Postsurgical pain
CRL March 2 2015. New Phase 3 trial initiated 1Q 2016. Enrollment to be completed early 2017.
EXPAREL
Single-dose injection femoral nerve block for total knee arthroplasty surgery

Latest News

  1. Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : April 25, 2017
  2. Can Pacira Pharmaceuticals' Exparel Reduce Opioid Abuse?
  3. Can Drugmakers Cure the Opioid Crisis?
  4. Pacira Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PCRX) : April 17, 2017
  5. Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PCRX-US : April 13, 2017
  6. Pacira Focuses on Lead Candidate Exparel's Label Expansion
  7. MonoSol Rx Appoints James S. Scibetta to Board of Directors
  8. Pacira Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference
  9. Pacira (PCRX) Down 7.2% Since Earnings Report: Can It Rebound?
  10. Anesthesia Can't Save This Biotech From Feeling Pain: Analyst
  11. Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use Nationwide
  12. Why Pacira Pharmaceuticals Stock Is Already Up 56% This Year
  13. Pacira Pharmaceuticals stock rises 2% on positive late-stage trial for opioid-reducing pain medication
  14. Phase 4 Study Shows EXPAREL® Versus an Active Comparator Significantly Reduces Opioid Consumption and Postsurgical Pain in Patients Undergoing Total Knee Arthroplasty
  15. Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
  16. Is Pacira Pharmaceuticals' Balance Sheet Safe?
  17. Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal Amount of 2.375% Convertible Senior Notes due 2022
  18. Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of Convertible Senior Notes
  19. ETFs with exposure to Pacira Pharmaceuticals, Inc. : March 6, 2017
  20. Red-Hot Biotech Companies Highlight Jefferies Top Stocks to Buy